Base de dados : MEDLINE
Pesquisa : C06.405.205.798 [Categoria DeCS]
Referências encontradas : 1127 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 113 ir para página                         

  1 / 1127 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28449762
[Au] Autor:Brignardello-Petersen R
[Ti] Título:No evidence of benefits from using enamel matrix derivative as an adjuvant treatment in patients with peri-implant mucositis.
[So] Source:J Am Dent Assoc;148(5):e58, 2017 05.
[Is] ISSN:1943-4723
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Mucosite
Estomatite
[Mh] Termos MeSH secundário: Implantes Dentários
Seres Humanos
Peri-Implantite
[Pt] Tipo de publicação:REVIEW; COMMENT
[Nm] Nome de substância:
0 (Dental Implants)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:D; IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE


  2 / 1127 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390445
[Au] Autor:Mackiewicz J; Rybarczyk-Kasiuchnicz A; Lasinska I; Mazur-Roszak M; Swiniuch D; Michalak M; Kazmierska J; Studniarek A; Krokowicz L; Bajon T
[Ad] Endereço:Department of Medical and Experimental Oncology, Heliodor Swiecicki Clinical, Hospital, Poznan University of Medical Sciences, Poland.
[Ti] Título:The comparison of acute toxicity in 2 treatment courses: Three-weekly and weekly cisplatin treatment administered with radiotherapy in patients with head and neck squamous cell carcinoma.
[So] Source:Medicine (Baltimore);96(51):e9151, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The most appropriate cisplatin treatment schedule delivered with radiotherapy in patients with head and neck squamous cell carcinoma (HNSCC) is unknown. The aim of this study was to compare the acute toxicity and its impact on the course of the treatment, administered cisplatin and radiation doses, the length of hospitalization and supportive drugs administration in patients with HNSCC receiving 2 different cisplatin treatment schedules administered with radiotherapy.In this retrospective analysis, 104 patients with HNSCC were enrolled. Patients received radiation concurrently with 100 mg/m cisplatin administered 3-weekly (n = 50; group A) or 35 to 40 mg/m cisplatin administered weekly (n = 54; group B). Chemoradiotherapy was performed in locally and/or regionally advanced disease (stage III-IV), in a definitive radical upfront setting (71.1%) or after surgical resection in patients with high-risk factors (28.8%).Both study groups were equally distributed in terms of age, gender, stage of the disease, Eastern Cooperative Oncology Group performance score, chronic diseases and primary tumor site. The schedule of cisplatin dosing did not influence the duration of hospitalization, the number of additional supportive drugs (antibiotics, opioids) administered or total doses of received radiotherapy. However, postponement of radiotherapy due to adverse events was significantly more frequent in patients treated with 35/40 mg/m (55.56% vs 32%; P = .015). Furthermore, patients treated with weekly treatment schedule received lower total cisplatin dose (160 mg/m) in comparison to those treated with the 3-weekly schedule (200 mg/m). Grade 3 and 4 mucositis occurred more frequently in patients treated in group A (70% vs 50%; P = .037). Leukopenia was also observed more frequently in group A (88% vs 72.2%; P = .04), however there was no difference in grade 3/4 leukopenia between both study arms. There was no statistically significant difference in any other adverse effects.These results do not demonstrate the advantage of modified weekly schedule over standard 3-weekly cisplatin treatment plan. However, severe mucositis occurred more frequently in patients receiving 3-weekly cisplatin, both chemotherapy schedules seemed to present similar toxicity. Due to conflicting efficacy and toxicity, the results and compliance of weekly and 3-weekly cisplatin schedules should be evaluated in further randomized, controlled trials and retrospective studies.
[Mh] Termos MeSH primário: Antineoplásicos/administração & dosagem
Carcinoma de Células Escamosas/tratamento farmacológico
Carcinoma de Células Escamosas/radioterapia
Quimiorradioterapia
Cisplatino/administração & dosagem
Neoplasias de Cabeça e Pescoço/tratamento farmacológico
Neoplasias de Cabeça e Pescoço/radioterapia
[Mh] Termos MeSH secundário: Adulto
Idoso
Relação Dose-Resposta a Droga
Esquema de Medicação
Feminino
Seres Humanos
Leucopenia/etiologia
Masculino
Meia-Idade
Mucosite/etiologia
Estudos Retrospectivos
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Antineoplastic Agents); Q20Q21Q62J (Cisplatin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009151


  3 / 1127 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28456772
[Au] Autor:Sano T; Utsumi D; Amagase K; Matsumoto K; Tominaga M; Higuchi K; Takeuchi T; Kato S
[Ad] Endereço:Division of Pathological Sciences, Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University, Yamashina, Kyoto, Japan. beatatsuo0507@gmail.com.
[Ti] Título:Lafutidine, a histamine H2 receptor antagonist with mucosal protective properties, attenuates 5-fluorouracil-induced intestinal mucositis in mice through activation of extrinsic primary afferent neurons.
[So] Source:J Physiol Pharmacol;68(1):79-90, 2017 Feb.
[Is] ISSN:1899-1505
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:Intestinal mucositis accompanied by severe diarrhea is one of the most common side effects during cancer chemotherapy. Lafutidine, a histamine H2 receptor antagonist with mucosal protective properties via sensory afferent neurons, is used for the treatment of upper gastrointestinal diseases. The present study investigated the effects of lafutidine on 5-fluorouracil (5-FU)-induced intestinal mucositis induced in mice. Male C57BL/6 wild-type (WT), sensory deafferented mice, and transient receptor potential vanilloid subfamily 1 knockout (TRPV1KO) mice were used. Animals were administered 5-FU once daily, while lafutidine and famotidine were administered twice daily for 6 days. Repeated administration of 5-FU caused severe intestinal mucositis, characterized by shortening of villi and destruction of crypts and was accompanied by diarrhea and body weight loss. Daily administration of lafutidine reduced the severity of intestinal mucositis, diarrhea and body weight loss in a dose-dependent manner, while famotidine had no effect on intestinal mucositis. The preventive effects of lafutidine were completely abolished in sensory deafferented and TRPV1-KO mice. Lafutidine significantly suppressed 5-FU-increased MPO activity and inflammatory cytokine expression on day 6, but not apoptosis induction in intestinal crypts on day 1. Lafutidine induced Alcian Blue and PAS-positive mucus production in the small intestine. These findings suggest that lafutidine attenuates 5-FU-induced intestinal mucositis, most likely by increasing mucus production via activation of sensory afferent neurons. Furthermore, intact TRPV1 signaling is essential for the activation of sensory afferent neurons induced by lafutidine. Therefore, lafutidine is more useful than other common antacids for the treatment of intestinal mucositis during cancer chemotherapy.
[Mh] Termos MeSH primário: Acetamidas/uso terapêutico
Diarreia/tratamento farmacológico
Antagonistas dos Receptores Histamínicos H2/uso terapêutico
Mucosite/tratamento farmacológico
Piperidinas/uso terapêutico
Piridinas/uso terapêutico
[Mh] Termos MeSH secundário: Acetamidas/farmacologia
Animais
Antimetabólitos Antineoplásicos
Diarreia/metabolismo
Diarreia/patologia
Famotidina/uso terapêutico
Fluoruracila
Antagonistas dos Receptores Histamínicos H2/farmacologia
Interleucina-1beta/genética
Intestinos/efeitos dos fármacos
Intestinos/metabolismo
Intestinos/patologia
Masculino
Camundongos Endogâmicos C57BL
Camundongos Knockout
Mucosite/induzido quimicamente
Mucosite/patologia
Peroxidase/metabolismo
Piperidinas/farmacologia
Piridinas/farmacologia
RNA Mensageiro/metabolismo
Fator de Necrose Tumoral alfa/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Acetamides); 0 (Antimetabolites, Antineoplastic); 0 (Histamine H2 Antagonists); 0 (IL1B protein, mouse); 0 (Interleukin-1beta); 0 (Piperidines); 0 (Pyridines); 0 (RNA, Messenger); 0 (Tumor Necrosis Factor-alpha); 49S4O7ADLC (lafutidine); 5QZO15J2Z8 (Famotidine); EC 1.11.1.7 (Peroxidase); U3P01618RT (Fluorouracil)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170501
[St] Status:MEDLINE


  4 / 1127 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28455268
[Au] Autor:Moon Y
[Ad] Endereço:Laboratory of Mucosal Exposome and Biomodulation, Department of Biomedical Sciences, Pusan National University School of Medicine, Yangsan, South Korea; Research Institute for Basic Sciences and Medical Research Institute, Pusan National University, Busan, South Korea; Immunoregulatory Therapeutics Group in Brain Busan 21 Project, Busan, South Korea. Electronic address: moon@pnu.edu.
[Ti] Título:NSAID-activated gene 1 and its implications for mucosal integrity and intervention beyond NSAIDs.
[So] Source:Pharmacol Res;121:122-128, 2017 Jul.
[Is] ISSN:1096-1186
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:In spite of the beneficial actions of non-steroid anti-inflammatory drugs (NSAIDs) in epithelial inflammation and cancers, their use is limited because of their cyclooxygenase-dependent or independent gastrointestinal toxicity. As an eicosanoid-independent mediator, NSAID-activated gene 1 (NAG-1) has been assessed for its involvement in cellular integrity and pathogenesis in mucosal inflammation and carcinogenesis. At the cellular levels, NAG-1 is involved in the cell growth regulation (cell death, cell cycle arrest, or proliferation) in epithelial and mesenchymal tissues. Moreover, NAG-1 can modulate inflammatory responses in either direct or indirect manner, which ultimately affects fibrogenic and tumorigenic processes in various disease states. Finally, NAG-1 has been assessed for its contribution to cellular behavior, such as the mobility of epithelial and malignant cells in response to the external insults or oncogenic stimulation in the mucosa. This review on the "Yin-Yang" nature of NAG-1-mediated responses provides comprehensive insights into therapeutic and diagnostic interventions for mucosal health and integrity in the human body.
[Mh] Termos MeSH primário: Carcinogênese/imunologia
Fator 15 de Diferenciação de Crescimento/imunologia
Mucosite/imunologia
Membrana Mucosa/imunologia
[Mh] Termos MeSH secundário: Animais
Carcinogênese/patologia
Movimento Celular
Proliferação Celular
Fibrose
Fator 15 de Diferenciação de Crescimento/análise
Seres Humanos
Inflamação/imunologia
Inflamação/patologia
Mucosite/patologia
Membrana Mucosa/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (GDF15 protein, human); 0 (Growth Differentiation Factor 15)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180105
[Lr] Data última revisão:
180105
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[St] Status:MEDLINE


  5 / 1127 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29277812
[Au] Autor:Eguchi K; Suzuki M; Ida S; Mori K; Imai H; Kudo S; Ando K; Higuchi K; Ebara T
[Ad] Endereço:Division of Head and Neck Surgery, Gunma Prefectural Cancer Center, Gunma, Japan kohtaro.eguchi@gmail.com.
[Ti] Título:Association Between Laryngopharyngeal Reflux and Radiation-induced Mucositis in Head and Neck Cancer.
[So] Source:Anticancer Res;38(1):477-480, 2018 01.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: We investigated whether laryngopharyngeal reflux (LPR) is a risk factor for radiation-induced mucositis. PATIENTS AND METHODS: This was a retrospective cohort study using our departmental database. The study included patients with stage I or II laryngeal and hypopharyngeal cancers treated with radiation therapy alone between April 2009 and March 2014. Based on endoscopic findings, baseline laryngeal signs were evaluated using the reflux finding score (RFS), and the severity of mucositis was assessed during and after radiation therapy. RESULTS: Fifty-eight patients were enrolled. Thirty-one patients were categorized as high RFS (LPR-likely), while 27 patients were categorized as low RFS (LPR-unlikely). Grade 3 mucositis occurred more frequently in the high RFS group (p<0.042). Furthermore, grade 3 mucositis developed earlier in the high RFS group (p<0.001). CONCLUSION: High RFS (i.e., increased likelihood of LPR) appears to be a potential risk factor for developing severe radiation-induced mucositis.
[Mh] Termos MeSH primário: Neoplasias de Cabeça e Pescoço/radioterapia
Mucosa Intestinal/efeitos da radiação
Refluxo Laringofaríngeo/patologia
Mucosa Bucal/efeitos da radiação
Mucosite/patologia
Lesões por Radiação/patologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Feminino
Seres Humanos
Mucosa Intestinal/patologia
Masculino
Meia-Idade
Mucosa Bucal/patologia
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180104
[Lr] Data última revisão:
180104
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171227
[St] Status:MEDLINE


  6 / 1127 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28941151
[Au] Autor:Tarek N; Hayes-Jordan A; Salvador L; McAleer MF; Herzog CE; Huh WW
[Ad] Endereço:Department of Pediatrics and Adolescent Medicine, Children's Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon.
[Ti] Título:Recurrent desmoplastic small round cell tumor responding to an mTOR inhibitor containing regimen.
[So] Source:Pediatr Blood Cancer;65(1), 2018 Jan.
[Is] ISSN:1545-5017
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Desmoplastic small round cell tumor (DSRCT) is a rare mesenchymal tumor that typically presents with multiple abdominal masses. Initial treatment is multimodal in nature. Patients with relapsed DSRCT have a poor prognosis, and there are no standard therapies. We report our experience with five patients treated with vinorelbine, cyclophosphamide, and temsirolimus (VCT). Median number of VCT courses delivered was 7 (range 4-14 courses), and partial response was observed in all patients. Median time to progression or relapse was 8.5 months (range 7-16 months). Neutropenia and mucositis were most common toxicities (n = 4 each).
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem
Tumor Desmoplásico de Pequenas Células Redondas/tratamento farmacológico
Recidiva Local de Neoplasia/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Criança
Ciclofosfamida/administração & dosagem
Ciclofosfamida/efeitos adversos
Tumor Desmoplásico de Pequenas Células Redondas/diagnóstico por imagem
Feminino
Seres Humanos
Masculino
Mucosite/induzido quimicamente
Mucosite/diagnóstico por imagem
Recidiva Local de Neoplasia/diagnóstico por imagem
Neutropenia/induzido quimicamente
Neutropenia/diagnóstico por imagem
Sirolimo/administração & dosagem
Sirolimo/efeitos adversos
Sirolimo/análogos & derivados
Vimblastina/administração & dosagem
Vimblastina/efeitos adversos
Vimblastina/análogos & derivados
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
5V9KLZ54CY (Vinblastine); 624KN6GM2T (temsirolimus); 8N3DW7272P (Cyclophosphamide); Q6C979R91Y (vinorelbine); W36ZG6FT64 (Sirolimus)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171129
[Lr] Data última revisão:
171129
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170924
[St] Status:MEDLINE
[do] DOI:10.1002/pbc.26768


  7 / 1127 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28937522
[Au] Autor:Villegas Rubio JA; Cacciavillano W; Rose A; Zubizarreta P; Scopinaro M
[Ad] Endereço:Hematology/Oncology Department, Professor Doctor Juan P. Garrahan Children Hospital, Buenos Aires, Argentina.
[Ti] Título:Ambulatory High-dose Methotrexate Administration in Pediatric Osteosarcoma Patients at a Single Institution in Argentina.
[So] Source:J Pediatr Hematol Oncol;39(7):e349-e352, 2017 Oct.
[Is] ISSN:1536-3678
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The purpose of this study was to evaluate the feasibility and safety of ambulatory high-dose methotrexate (HDMTX) administration with oral hydration, alkalinization, and leucovorin rescue. HDMTX (12 g/m) was given intravenously over 4 hours after urine alkalinization. Families and patients were instructed to continue ambulatory oral hydration and alkalinization to monitor urine pH and to adjust bicarbonate according to our institution's treatment algorithm. Clinical status and MTX levels were controlled every 24 hours, and oral leucovorin dose was adjusted accordingly. RESULTS: From April 2007 to December 2010, 150 of 447 courses of HDMTX (31.4%) were given on an outpatient basis, and 91.2% were successfully completed. The main causes of failure were poor oral tolerance (n=6) and fever (n=4). Most patients (81%) had MTX levels of <10 µmol/L 24 hours post-HDMTX; only in 1 course the levels were >50 µmol/L (50.96 µmol/L). Neutropenia grade III/IV was observed in 18.3% of the courses, grade III/IV leukopenia in 2.7%, and grade III/IV thrombocytopenia and anemia in 4.7%. Around 39% were associated with grade III/IV hepatic toxicity (asymptomatic hypertransaminasemia), grade III-IV gastrointestinal toxicity (vomiting and diarrhea) (5%), grade III-IV mucositis (4%), and none of the patients developed renal toxicity. CONCLUSIONS: Ambulatory HDMTX administration is feasible and safe in a population with poor resources in a developing country.
[Mh] Termos MeSH primário: Metotrexato/administração & dosagem
Osteossarcoma/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Algoritmos
Assistência Ambulatorial
Anemia/induzido quimicamente
Antiácidos/administração & dosagem
Argentina
Doença Hepática Induzida por Substâncias e Drogas
Criança
Diarreia/induzido quimicamente
Feminino
Seres Humanos
Concentração de Íons de Hidrogênio
Leucovorina/administração & dosagem
Leucopenia/induzido quimicamente
Masculino
Metotrexato/efeitos adversos
Mucosite/induzido quimicamente
Neutropenia/induzido quimicamente
Osteossarcoma/complicações
Estudos Retrospectivos
Trombocitopenia/induzido quimicamente
Vômito/induzido quimicamente
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antacids); Q573I9DVLP (Leucovorin); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171025
[Lr] Data última revisão:
171025
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170923
[St] Status:MEDLINE
[do] DOI:10.1097/MPH.0000000000000922


  8 / 1127 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28835391
[Au] Autor:Genda T; Sasaki Y; Kondo T; Hino S; Nishimura N; Tsukahara T; Sonoyama K; Morita T
[Ad] Endereço:Graduate School of Science and Technology and.
[Ti] Título:Fructo-oligosaccharide-Induced Transient Increases in Cecal Immunoglobulin A Concentrations in Rats Are Associated with Mucosal Inflammation in Response to Increased Gut Permeability.
[So] Source:J Nutr;147(10):1900-1908, 2017 Oct.
[Is] ISSN:1541-6100
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The mechanism underlying transient increases in immunoglobulin (Ig) A concentrations in the cecal contents of rats fed fructo-oligosaccharide (FOS) is unclear. This study was designed to test whether increased IgA concentrations represent one aspect of the inflammatory response to increased permeability induced by FOS in the cecum. Seven-week-old male Wistar rats were fed a fiber-free semipurified diet (FFP) with or without supplemental FOS (60 g/kg diet) for 9 or 58 d [experiment (expt.) 1], 7 d (expt. 2), or 7 or 56 d (expt. 3). In addition to measuring IgA concentrations in cecal content, we assessed gut permeability, inflammatory responses (expt. 1), the number of IgA plasma cells in the cecal lamina propria, polymeric Ig receptor (pIgR) expression in the cecal mucosa (expt. 2), and the condition of the cecal mucus layer (expt. 3). The cecal IgA concentration in the FOS-fed rats was 15-fold higher than that of the rats fed FFP for 9 d ( < 0.05). Gut permeability estimated by urinary chromium-EDTA excretion, bacterial translocation to mesenteric lymph nodes, myeloperoxidase activity, and expression of inflammatory cytokine genes in the cecal mucosa was greater in the FOS-fed rats than in the rats fed FFP for 9 d. These effects were not observed in the rats fed FOS for 58 d (expt. 1). Accompanying the higher cecal IgA concentration, pIgR protein and the number of IgA plasma cells in the cecal mucosa were higher in the FOS-fed rats than in the rats fed FFP for 7 d (expt. 2). Destruction of the mucus layer on the epithelial surface, as evidenced by Alcian blue staining in the cecal sections, was evident in the rats fed FOS for 7 d, but the mucus layer appeared normal in the rats fed FOS for 56 d (expt. 3). These findings suggest that transient increases in cecal IgA concentrations induced by FOS in rats are associated with mucosal inflammation in response to increased gut permeability; these are presumably evoked by disruption of the cecal mucus barrier. The observed responses could contribute to the maturation of the gut immune system.
[Mh] Termos MeSH primário: Ceco/metabolismo
Frutose/farmacologia
Imunoglobulina A/metabolismo
Mucosa Intestinal/efeitos dos fármacos
Mucosite/metabolismo
Oligossacarídeos/farmacologia
Prebióticos
[Mh] Termos MeSH secundário: Animais
Translocação Bacteriana
Ceco/efeitos dos fármacos
Ceco/patologia
Citocinas/metabolismo
Frutose/imunologia
Inflamação/etiologia
Inflamação/metabolismo
Inflamação/patologia
Mucosa Intestinal/imunologia
Mucosa Intestinal/metabolismo
Mucosa Intestinal/patologia
Linfonodos
Masculino
Mesentério
Mucosite/etiologia
Mucosite/patologia
Oligossacarídeos/imunologia
Permeabilidade
Peroxidase/metabolismo
Ratos Wistar
Receptores de Imunoglobulina Polimérica/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cytokines); 0 (Immunoglobulin A); 0 (Oligosaccharides); 0 (Prebiotics); 0 (Receptors, Polymeric Immunoglobulin); 30237-26-4 (Fructose); EC 1.11.1.7 (Peroxidase)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171012
[Lr] Data última revisão:
171012
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170825
[St] Status:MEDLINE
[do] DOI:10.3945/jn.117.253955


  9 / 1127 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28678827
[Au] Autor:Reyes-Gibby CC; Melkonian SC; Wang J; Yu RK; Shelburne SA; Lu C; Gunn GB; Chambers MS; Hanna EY; Yeung SJ; Shete S
[Ad] Endereço:Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
[Ti] Título:Identifying novel genes and biological processes relevant to the development of cancer therapy-induced mucositis: An informative gene network analysis.
[So] Source:PLoS One;12(7):e0180396, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Mucositis is a complex, dose-limiting toxicity of chemotherapy or radiotherapy that leads to painful mouth ulcers, difficulty eating or swallowing, gastrointestinal distress, and reduced quality of life for patients with cancer. Mucositis is most common for those undergoing high-dose chemotherapy and hematopoietic stem cell transplantation and for those being treated for malignancies of the head and neck. Treatment and management of mucositis remain challenging. It is expected that multiple genes are involved in the formation, severity, and persistence of mucositis. We used Ingenuity Pathway Analysis (IPA), a novel network-based approach that integrates complex intracellular and intercellular interactions involved in diseases, to systematically explore the molecular complexity of mucositis. As a first step, we searched the literature to identify genes that harbor or are close to the genetic variants significantly associated with mucositis. Our literature review identified 27 candidate genes, of which ERCC1, XRCC1, and MTHFR were the most frequently studied for mucositis. On the basis of this 27-gene list, we used IPA to generate gene networks for mucositis. The most biologically significant novel molecules identified through IPA analyses included TP53, CTNNB1, MYC, RB1, P38 MAPK, and EP300. Additionally, uracil degradation II (reductive) and thymine degradation pathways (p = 1.06-08) were most significant. Finally, utilizing 66 SNPs within the 8 most connected IPA-derived candidate molecules, we conducted a genetic association study for oral mucositis in the head and neck cancer patients who were treated using chemotherapy and/or radiation therapy (186 head and neck cancer patients with oral mucositis vs. 699 head and neck cancer patients without oral mucositis). The top ranked gene identified through this association analysis was RB1 (rs2227311, p-value = 0.034, odds ratio = 0.67). In conclusion, gene network analysis identified novel molecules and biological processes, including pathways related to inflammation and oxidative stress, that are relevant to mucositis development, thus providing the basis for future studies to improve the management and treatment of mucositis in patients with cancer.
[Mh] Termos MeSH primário: Antineoplásicos/efeitos adversos
Redes Reguladoras de Genes
Predisposição Genética para Doença
Neoplasias de Cabeça e Pescoço/tratamento farmacológico
Mucosite/induzido quimicamente
[Mh] Termos MeSH secundário: Antineoplásicos/uso terapêutico
Neoplasias de Cabeça e Pescoço/genética
Seres Humanos
Mucosite/genética
Mucosite/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antineoplastic Agents)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171002
[Lr] Data última revisão:
171002
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170706
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0180396


  10 / 1127 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28536886
[Au] Autor:Kuiken NSS; Rings EHHM; Blijlevens NMA; Tissing WJE
[Ad] Endereço:Department of Pediatric Oncology, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, PO Box 30001, 9700 RB, Groningen, The Netherlands.
[Ti] Título:Biomarkers and non-invasive tests for gastrointestinal mucositis.
[So] Source:Support Care Cancer;25(9):2933-2941, 2017 Sep.
[Is] ISSN:1433-7339
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Gastrointestinal mucositis is a complex inflammatory reaction of the mucous membranes, a side effect of both chemotherapy and radiotherapy. Currently, assessment scales are used to diagnose mucositis. However, a biomarker which would determine whether there is mucositis and thereby establish the severity objectively would be very useful. This will give the opportunity to evaluate studies, to determine risk factors and incidence, and it will make it possible to compare studies. Moreover, this biomarker might improve clinical management for patients. In this paper, we reviewed studies concerning potential biomarkers in blood samples and fecal samples, and potential tests in breath samples and urine samples. We include biomarkers and tests studied in animal models and/or in clinical trials, and discuss the validity, diagnostic accuracy, and applicability.
[Mh] Termos MeSH primário: Biomarcadores/sangue
Neoplasias Gastrointestinais/complicações
Mucosite/diagnóstico
[Mh] Termos MeSH secundário: Animais
Seres Humanos
Incidência
Mucosite/etiologia
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Biomarkers)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171108
[Lr] Data última revisão:
171108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170525
[St] Status:MEDLINE
[do] DOI:10.1007/s00520-017-3752-2



página 1 de 113 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde